Leading global anti-viral products by market share 2017 and 2024
This statistic displays the top 5 global anti-viral products based on their market share worldwide in 2017, and a projection for 2024. Gilead Sciences' Genvoya is expected to accumulate around 8.5 percent of the global market in anti-viral revenues by 2024. In the last years, Gilead Sciences’ Harvoni accounted for the largest share by a single drug of the world’s market share of anti-virals. Harvoni or Ledipasvir is used in the treatment of hepatitis C. This product was first marketed in October 2014. Hepatitis C is an infectious disease that can scar the liver and lead to cirrhosis.